These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

862 related articles for article (PubMed ID: 20124451)

  • 41. 4-Bromophenylhydrazinyl benzenesulfonylphenylureas as indoleamine 2,3-dioxygenase inhibitors with in vivo target inhibition and anti-tumor efficacy.
    Lin SY; Yeh TK; Song JS; Hung MS; Cheng MF; Liao FY; Li AS; Cheng SY; Lin LM; Chiu CH; Wu MH; Lin YJ; Hsiao W; Sun M; Wang YH; Huang CH; Tang YC; Chang HH; Huang ZT; Chao YS; Shih C; Pan SL; Wu SY; Kuo CC; Ueng SH
    Bioorg Chem; 2018 Apr; 77():600-607. PubMed ID: 29494816
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Apicomplexan parasite, Eimeria falciformis, co-opts host tryptophan catabolism for life cycle progression in mouse.
    Schmid M; Lehmann MJ; Lucius R; Gupta N
    J Biol Chem; 2012 Jun; 287(24):20197-207. PubMed ID: 22535959
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Indoleamine 2,3-Dioxygenase (IDO) Inhibition as a Strategy to Augment Cancer Immunotherapy.
    Yentz S; Smith D
    BioDrugs; 2018 Aug; 32(4):311-317. PubMed ID: 29980987
    [TBL] [Abstract][Full Text] [Related]  

  • 44. In vivo metabolism of tryptophan in meningiomas is mediated by indoleamine 2,3-dioxygenase 1.
    Zitron IM; Kamson DO; Kiousis S; Juhász C; Mittal S
    Cancer Biol Ther; 2013 Apr; 14(4):333-9. PubMed ID: 23358471
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Design and Synthesis of Indoleamine 2,3-Dioxygenase 1 Inhibitors and Evaluation of Their Use as Anti-Tumor Agents.
    Wen H; Liu Y; Wang S; Wang T; Zhang G; Chen X; Li Y; Cui H; Lai F; Sheng L
    Molecules; 2019 Jun; 24(11):. PubMed ID: 31195673
    [TBL] [Abstract][Full Text] [Related]  

  • 46. 4,6-Substituted-1H-Indazoles as potent IDO1/TDO dual inhibitors.
    Yang L; Chen Y; He J; Njoya EM; Chen J; Liu S; Xie C; Huang W; Wang F; Wang Z; Li Y; Qian S
    Bioorg Med Chem; 2019 Mar; 27(6):1087-1098. PubMed ID: 30773421
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Highlights at the gate of tryptophan catabolism: a review on the mechanisms of activation and regulation of indoleamine 2,3-dioxygenase (IDO), a novel target in cancer disease.
    Macchiarulo A; Camaioni E; Nuti R; Pellicciari R
    Amino Acids; 2009 Jul; 37(2):219-29. PubMed ID: 18612775
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Indoleamine 2,3 dioxygenase-mediated tryptophan catabolism regulates accumulation of Th1/Th17 cells in the joint in collagen-induced arthritis.
    Criado G; Simelyte E; Inglis JJ; Essex D; Williams RO
    Arthritis Rheum; 2009 May; 60(5):1342-51. PubMed ID: 19404944
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Preclinical Characterization of Linrodostat Mesylate, a Novel, Potent, and Selective Oral Indoleamine 2,3-Dioxygenase 1 Inhibitor.
    Balog A; Lin TA; Maley D; Gullo-Brown J; Kandoussi EH; Zeng J; Hunt JT
    Mol Cancer Ther; 2021 Mar; 20(3):467-476. PubMed ID: 33298590
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Deficient tryptophan catabolism along the kynurenine pathway reveals that the epididymis is in a unique tolerogenic state.
    Jrad-Lamine A; Henry-Berger J; Gourbeyre P; Damon-Soubeyrand C; Lenoir A; Combaret L; Saez F; Kocer A; Tone S; Fuchs D; Zhu W; Oefner PJ; Munn DH; Mellor AL; Gharbi N; Cadet R; Aitken RJ; Drevet JR
    J Biol Chem; 2011 Mar; 286(10):8030-8042. PubMed ID: 21189261
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Indoleamine 2,3-Dioxygenase 1: A Promising Therapeutic Target in Malignant Tumor.
    Song X; Si Q; Qi R; Liu W; Li M; Guo M; Wei L; Yao Z
    Front Immunol; 2021; 12():800630. PubMed ID: 35003126
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Selective inhibition of IDO1, D-1-methyl-tryptophan (D-1MT), effectively increased EpCAM/CD3-bispecific BiTE antibody MT110 efficacy against IDO1
    Hong R; Zhou Y; Tian X; Wang L; Wu X
    Int Immunopharmacol; 2018 Jan; 54():118-124. PubMed ID: 29128855
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Quantification of IDO1 enzyme activity in normal and malignant tissues.
    Zhai L; Ladomersky E; Bell A; Dussold C; Cardoza K; Qian J; Lauing KL; Wainwright DA
    Methods Enzymol; 2019; 629():235-256. PubMed ID: 31727243
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Reversal of indoleamine 2,3-dioxygenase-mediated cancer immune suppression by systemic kynurenine depletion with a therapeutic enzyme.
    Triplett TA; Garrison KC; Marshall N; Donkor M; Blazeck J; Lamb C; Qerqez A; Dekker JD; Tanno Y; Lu WC; Karamitros CS; Ford K; Tan B; Zhang XM; McGovern K; Coma S; Kumada Y; Yamany MS; Sentandreu E; Fromm G; Tiziani S; Schreiber TH; Manfredi M; Ehrlich LIR; Stone E; Georgiou G
    Nat Biotechnol; 2018 Sep; 36(8):758-764. PubMed ID: 30010674
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Involvement of Indoleamine-2,3-Dioxygenase and Kynurenine Pathway in Experimental Autoimmune Encephalomyelitis in Mice.
    Zarzecki MS; Cattelan Souza L; Giacomeli R; Silva MRP; Prigol M; Boeira SP; Jesse CR
    Neurochem Res; 2020 Dec; 45(12):2959-2977. PubMed ID: 33040279
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Salinomycin promotes T-cell proliferation by inhibiting the expression and enzymatic activity of immunosuppressive indoleamine-2,3-dioxygenase in human breast cancer cells.
    Ebokaiwe AP; Njoya EM; Sheng Y; Zhang Z; Li S; Zhou Z; Qiang Z; Peng T; Hussein AA; Zhang G; Lu X; Li L; Wang F
    Toxicol Appl Pharmacol; 2020 Oct; 404():115203. PubMed ID: 32822738
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Inhibition of Tryptophan-Dioxygenase Activity Increases the Antitumor Efficacy of Immune Checkpoint Inhibitors.
    Schramme F; Crosignani S; Frederix K; Hoffmann D; Pilotte L; Stroobant V; Preillon J; Driessens G; Van den Eynde BJ
    Cancer Immunol Res; 2020 Jan; 8(1):32-45. PubMed ID: 31806638
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Discovery of novel hydroxyamidine derivatives as indoleamine 2,3-dioxygenase 1 inhibitors with in vivo anti-tumor efficacy.
    Liu C; Nan Y; Xia Z; Gu K; Chen C; Dong X; Ju D; Zhao W
    Bioorg Med Chem Lett; 2020 Apr; 30(8):127038. PubMed ID: 32088128
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Evaluation of radiofluorinated carboximidamides as potential IDO-targeted PET tracers for cancer imaging.
    Huang X; Pan Z; Doligalski ML; Xiao X; Ruiz E; Budzevich MM; Tian H
    Oncotarget; 2017 Jul; 8(29):46900-46914. PubMed ID: 28159919
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Targeting Indoleamine 2,3-Dioxygenase in Cancer Models Using the Novel Small Molecule Inhibitor NTRC 3883-0.
    Grobben Y; de Man J; van Doornmalen AM; Muller M; Willemsen-Seegers N; Vu-Pham D; Mulder WR; Prinsen MBW; de Wit J; Sterrenburg JG; van Cauter F; den Ouden JE; van Altena AM; Massuger LF; Uitdehaag JCM; Buijsman RC; Zaman GJR
    Front Immunol; 2020; 11():609490. PubMed ID: 33584686
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 44.